International Textbook of Diabetes Mellitus, 4th Ed., Chapter 12 – Mechanisms of insulin signal transduction

References:

1. Avruch J: Insulin signal transduction through protein kinase cascades. *Molecular and Cellular Biochemistry* 1998;182:31 – 48.
2. Reaven GM: Pathophysiology of insulin resistance in human disease. *Physiological Reviews* 1995;75:473–486.
3. Jacobs S, Cuatrecasas P: Insulin receptor: structure and function. *Endocrine Reviews* 1981;2:251–263.
4. Zhang B, Roth RA: Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptor. *Biochemistry* 1991;30:5113–5117.
5. Kasuga M, Karlsson FA, Kahn CR: Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. *Science* 1982;215:185 – 187.
6. Roth RA, Cassell DJ: Insulin receptor: evidence that it is a protein kinase. *Science* 1983;219:299–301.
7. Frattali AL, Treadway JL, Pessin JE: Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation. *The Journal of Biological Chemistry* 1992;267:19521 – 19528.
8. Rosen OM: Banting Lecture 1989. Structure and function of insulin receptors. *Diabetes* 1989;38:1508 – 1511.
9. Cheatham B, Kahn CR: Insulin action and the insulin signaling network. *Endocrine Reviews* 1995;16:117 – 142.
10. Danielsen AG, Liu F, Hosomi Y, et al.: Activation of protein kinase C alpha inhibits signaling by members of the insulin receptor family. *The Journal of Biological Chemistry* 1995;270: 21600 – 21605.
11. Ullrich A, Bell JR, Chen EY, et al.: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 1985;313:756 – 761.
12. Frasca F, Pandini G, Scalia P, et al.: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Molecular and Cellular Biology* 1999;19:3278 – 3288.
13. Savkur RS, Philips AV, Cooper TA: Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. *Nature Genetics* 2001;29:40–47.
14. Soos MA, Siddle K: Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. *Biochemistry Journal* 1989; 263:553 – 563.

15. Soos MA, Whittaker J, Lammers R,etal.:Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. *Biochemistry Journal* 1990;270:383 – 390.
16. Whittaker J, Soos MA, Siddle K: Hybrid insulin receptors. Molecular mechanisms of negative-dominant mutations in receptor-mediated insulin resistance. *Diabetes Care* 1990;13: 576 – 581.
17. Soos MA, Field CE, Siddle K: Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. *Biochemistry Journal* 1993;290 (Pt 2):419–426.
18. Sherajee SJ, Fujita Y, Rafiq K, et al.: Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2012;32:257–263.
19. Abbas A, Imrie H, Viswambharan H, et al.: The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. *Diabetes* 2011;60:2169 – 2178.
20. Sprynski AC, Hose D, Kassambara A, et al.: Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. *Leukemia* 2010;24:1940–1950.
21. Zhang G, Li X, Zhang L, et al.: The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells. *Cancer Genetics and Cytogenetics* 2010;200:140 – 148.
22. Hunter RW, Hers I: Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. *Journal of Thrombosis and Haemostasis* 2009;7:2123 – 2130.
23. Taylor SI, Wertheimer E, Hone J, et al.: Mutations in the insulin receptor gene in patients with genetic syndromes of extreme insulin resistance. In: Draznin B, LeRoith D (eds.) *Molecular Biology of Diabetes, Vol. 2*. Philadelphia, PA: Humana Press, 1994, pp. 1 – 23.
24. Kahn CR, Flier JS, Bar RS, et al.: The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. *New England Journal of Medicine* 1976;294:739 – 745.
25. O'Rahilly S, Moller D: Mutant insulin receptors in syndromes of insulin resistance. *Clinical Endocrinology (Oxf)* 1992;36:121–132.
26. Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. *Science* 1997;278:2075–2080.
27. White MF: IRS proteins and the common path to diabetes. *American Journal of Physiology - Endocrinology and Metabolism* 2002;283:E413 – 422.
28. Virkamaki A, Ueki K, Kahn CR: Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. *Journal of Clinical Investigation* 1999;103:931–943.
29. Sun XJ, Rothenberg P, Kahn CR, et al.: Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. *Nature* 1991;352:73–77.

30. Sun XJ, Wang LM, Zhang Y, et al.: Role of IRS-2 in insulin and cytokine signalling. *Nature* 1995;377:173–177.
31. Lavan BE, Lane WS, Lienhard GE: The 60-Kda phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. *The Journal of Biological Chemistry* 1997;272:11439–11443.
32. Lavan BE, Fantin VR, Chang ET, et al.:A novel 160-Kda Phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. *The Journal of Biological Chemistry* 1997;272:21403–21407.
33. Cai D, Dhe-Paganon S, Melendez PA, et al.: Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. *The Journal of Biological Chemistry* 2003;278:25323–25330.
34. Pelicci G, Lanfrancone L, Grignani F, et al.: A novel transforming protein (Shc) with an Sh2 domain is implicated in mitogenic signal transduction. *Cell* 1992;70:93–104.
35. Holgado-Madruga M, Emlet DR, Moscatello DK, et al.: A Grb2-associated docking protein in EGF- and insulin-receptor signalling. *Nature* 1996;379:560–564.
36. Fujioka Y, Matozaki T, Noguchi T, et al.: A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. *Molecular and Cellular Biology* 1996;16:6887–6899.
37. Kharitonenkov A, Chen Z, Sures I, et al.: A family of proteins that inhibit signalling through tyrosine kinase receptors. *Nature* 1997;386:181 – 186.
38. Ribon V, Saltiel AR: Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of C-Cbl in 3T3-L1 adipocytes. *Biochemistry Journal* 1997;324(Pt 3):839–845.
39. Baumann CA, Ribon V, Kanzaki M, et al.: CAP defines a second signalling pathway required for insulin-stimulated glucose transport. *Nature* 2000;407:202 – 207.
40. Moodie SA, Alleman-Sposeto J, Gustafson TA (1999) Identification of the Aps protein as a novel insulin receptor substrate. *The Journal of Biological Chemistry* 1999;274:11186 – 11193.
41. Van Obberghen E, Baron V, Delahaye L, et al.: Surfing the insulin signaling web. *European Journal of Clinical Investigation* 2001;31:966 – 977.
42. Carpino N, Wisniewski D, Strife A, et al.: p62(Dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. *Cell* 1997;88:197 – 204.
43. Collett MS, Erikson RL: Protein kinase activity associated with the avian sarcoma virus Src gene product. *PNAS* 1978;75:2021 – 2024.
44. Tamemoto H, Kadowaki T, Tobe K, et al.: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. *Nature* 1994;372:182–186.

45. Araki E, Lipes MA, Patti ME, et al.: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. *Nature* 1994;372:186–190.
46. Withers DJ, Gutierrez JS, Towery H, et al.: Disruption of IRS-2 causes type 2 diabetes in mice. *Nature* 1998;391:900–904.
47. Versteyhe S, Blanquart C, Hampe C, et al.: Insulin receptor substrates-5 and -6 are poor substrates for the insulin receptor. *Molecular Medicine Reports* 2010;3:189–193.
48. Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E: Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591 – 786. *The Journal of Biological Chemistry* 1996;271:5980–5983.
49. Sawka-Verhelle D, Baron V, Mothe I, et al.: Tyr 624 and Tyr 628 in insulin receptor substrate-2 mediate its association with the insulin receptor. *The Journal of Biological Chemistry* 1997;272:16414 – 16420.
50. Wu J, Tseng YD, Xu CF, et al.: Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. *Nature Structural & Molecular Biology* 2008;15:251–258.
51. Hirashima Y, Tsuruzoe K, KodamaS,etal.: Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. *Journal of Endocrinology* 2003;179:253 – 266.
52. Rui L, Yuan M,Frantz D,etal.:SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. *The Journal of Biological Chemistry* 2002;277:42394–42398.
53. Shimomura I, Matsuda M, Hammer RE, et al.: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. *Molecular Cell* 2000;6:77 – 86.
54. Stoker AW: Protein tyrosine phosphatases and signalling. *Journal of Endocrinology* 2005;185:19–33.
55. Ball LE, Berkaw MN, Buse MG: Identification of the major site of O-linked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. *Molecular Cell Proteomics* 2006;5:313 – 323.
56. Carvalho-Filho MA, Ueno M, Carvalheira JB, et al.: Targeted disruption of iNOS prevents LPS-induced S-nitrosation of IRbeta/IRS1 and Akt and insulin resistance in muscle of mice. *American Journal of Physiology - Endocrinology and Metabolism* 2006;291:E476 – 482.
57. Badal S, Brown PD, Ragoobirsingh D: Nitric oxide agents impair insulin-mediated signal transduction in rat skeletal muscle. *BMC Biochemistry* 2006;7:17.
58. Crowder RJ, Enomoto H, Yang M, et al.: Dok-6, a novel p62dok family member, promotes Ret-mediated neurite outgrowth. *The Journal of Biological Chemistry* 2004;279:42072 – 42081.
59. Wick MJ, Dong LQ, Hu D, et al.: Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting

insulin-stimulated activation of Ras and Akt. *The Journal of Biological Chemistry* 2001;276:42843 – 42850.
60. Egan SE, Weinberg RA: The pathway to signal achievement. *Nature* 1993;365:781 – 783.
61. Boulton TG, Nye SH, Robbins DJ, et al.: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. *Cell* 1991;65:663 – 675.
62. Hausdorff SF, Frangioni JV, Birnbaum MJ: Role of p21ras in insulin-stimulated glucose transport in 3T3-L1 adipocytes. *The Journal of Biological Chemistry* 1994;269:21391–21394.
63. Lazar DF, Wiese RJ, Brady MJ, et al.: Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. *The Journal of Biological Chemistry* 1995;270:20801 – 20807.
64. Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. *Annual Review of Biochemistry* 1998;67:481–507.
65. Backer JM, Myers MG, Jr, Shoelson SE, et al.: Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. *EMBO Journal* 1992;11:3469–3479.
66. Khan AH, Pessin JE: Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. *Diabetologia* 2002;45:1475 – 1483.
67. Mauvais-Jarvis F, Ueki K, Fruman DA, et al.: Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. *Journal of Clinical Investigation* 2002;109:141–149.
68. Taniguchi CM, Aleman JO, Ueki K,et al.:The p85 alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. *Molecular and Cellular Biology* 2007;27:2830 – 2840.
69. Taniguchi CM, Tran TT, Kondo T, et al.: Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. *PNAS* 2006;103:12093–12097.
70. Taniguchi CM, Winnay J, Kondo T, et al.: The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. *Cancer Research* 2010;70:5305–5315.
71. Ueki K, Fruman DA, Brachmann SM, et al.: Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. *Molecular and Cellular Biology* 2002;22:965–977.
72. Ueki K, Fruman DA, Yballe CM, et al.: Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. *The Journal of Biological Chemistry* 2003;278:48453 – 48466.
73. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR: Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by

three different gene products of the p85alpha regulatory subunit. *Molecular Cell Biology* 2000;20:8035 – 8046 .
74. Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. *The Journal of Biological Chemistry* 1999;274:8347 – 8350.
75. Cantley LC: The phosphoinositide 3-kinase pathway. *Science* 2002;296:1655 – 1657.
76. Stralfors P: Insulin second messengers. *Bioessays* 1997;19:327 – 335.
77. Zhou QL, Park JG, Jiang ZY, et al.: Analysis of insulin signalling by RNAi-based gene silencing. *Biochemical Society Transactions* 2004;32:817 – 821.
78. Bellacosa A, Testa JR, Staal SP, Tsichlis PN: A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an Sh2-like region. *Science* 1991;254:274 – 277.
79. Bellacosa A, Chan TO, Ahmed NN, et al.: Akt activation by growth factors is a multiple-step process: the role of the Ph domain. *Oncogene* 1998;17:313 – 325.
80. Kohn AD, Takeuchi F, Roth RA: Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. *The Journal of Biological Chemistry* 1996;271:21920 – 21926.
81. Summers SA, Yin VP, Whiteman EL, et al.: Signaling pathways mediating insulin-stimulated glucose transport. *Annals of the N Y Academy of Sciences* 1999;892:169 – 186.
82. Le Good JA, Ziegler WH, Parekh DB, et al.: Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* 1998;281:2042 – 2045.
83. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. *Current Opinion in Cell Biology* 2005;17:596 – 603.
84. Kohn AD, Summers SA, Birnbaum MJ, Roth RA: Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. *The Journal of Biological Chemistry* 1996;271:31372 – 31378.
85. Calera MR, Martinez C, Liu H, et al.: Insulin increases the associa- tion of Akt-2 with Glut4-containing vesicles. *The Journal of Biological Chemistry* 1998;273:7201 – 7204.
86. Kitamura T, Ogawa W, Sakaue H, et al.: Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. *Molecular and Cellular Biology* 1998;18:3708 – 3717.
87. Kim YB, Nikoulina SE, Ciaraldi TP, et al.: Normal insulin- dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. *Journal of Clinical Investigation* 1999;104:733 – 741.

88. Cho H, Mu J, Kim JK, et al.: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science* 2001;292:1728 – 1731.
89. Whiteman EL, Cho H, Birnbaum MJ: Role of Akt/protein kinase B in metabolism. *Trends in Endocrinology & Metabolism* 2002;13:444 – 451.
90. Cross DA, Alessi DR, Cohen P, et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 1995;378:785 – 789.
91. Summers SA, Kao AW, Kohn AD, et al.: The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. *The Journal of Biological Chemistry* 1999;274:17934 – 17940.
92. Scott PH, Brunn GJ, Kohn AD, et al.: Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. *PNAS* 1998;95:7772 – 7777.
93. Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. *Genes Dev* 2001;15:807 – 826.
94. Fulton D, Gratton JP, McCabe TJ, et al.: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature* 1999;399:597 – 601.
95. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. *Genes & Development* 1999;13:2905 – 2927.
96. Nakae J, Park BC, Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a wortmannin-sensitive pathway. *The Journal of Biological Chemistry* 1999;274:15982 – 15985.
97. Biggs WH, 3rd, Meisenhelder J, Hunter T, et al.: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. *PNAS* 1999;96:7421 – 7426.
98. Standaert ML, Galloway L, Karnam P, et al.: Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. *The Journal of Biological Chemistry* 1997;272:30075 – 30082.
99. Kotani K, Ogawa W, Matsumoto M, et al.: Requirement of atypical protein kinase c lambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. *Molecular and Cellular Biology* 1998;18:6971 – 6982.
100. Farese RV: Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. *American Journal of Physiology - Endocrinology and Metabolism* 2002;283:E1 – 11.
101. Tsuru M, Katagiri H, Asano T, et al.: Role of PKC isoforms in glucose transport in 3T3-L1 adipocytes: insignificance of atypical PKC. *American Journal of Physiology - Endocrinology and Metabolism* 2002;283:E338 – 345.

102. Mendez R, Kollmorgen G, White MF, Rhoads RE: Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin. *Molecular and Cellular Biology* 1997;17:5184 – 5192.
103. Isakoff SJ, Taha C, Rose E, et al.: The inability of phosphatidylinositol 3-kinase activation to stimulate Glut4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. *PNAS* 1995;92:10247 – 10251.
104. Guilherme A, Czech MP: Stimulation of IRS-1-associated phosphatidylinositol 3-kinase and Akt/protein kinase B but not glucose transport by beta1-integrin signaling in rat adipocytes. *The Journal of Biological Chemistry* 1998;273:33119 – 33122.
105. Watson RT, Pessin JE: Intracellular organization of insulin signaling and Glut4 translocation. *Recent Progress in Hormone Research* 2001;56:175 – 193.
106. Saltiel AR, Pessin JE: Insulin signaling pathways in time and space. *Trends in Cell Biology* 2002;12:65–71.
107. Krook A, Whitehead JP, Dobson SP, et al.: Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphoinositide 3-kinase activation alone is not suffi- cient for the mediation of insulin's metabolic and mitogenic effects. *The Journal of Biological Chemistry* 1997;272:30208 – 30214.
108. Jiang T, Sweeney G, Rudolf MT, et al.: Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate. *The Journal of Biological Chemistry* 1998;273:11017 – 11024.
109. Liu J, Kimura A, Baumann CA, Saltiel AR: APS facilitates C-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes. *Molecular and Cellular Biology* 2002;22:3599 – 3609.
110. Ribon V, Printen JA, Hoffman NG, et al.: A novel, multifunctional C-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes. *Molecular and Cellular Biology* 1998;18:872 – 879.
111. Bickel PE: Lipid rafts and insulin signaling. *American Journal of Physiology - Endocrinology and Metabolism* 2002;282:E1 – E10.
112. Chiang SH, Baumann CA, Kanzaki M, et al.: Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. *Nature* 2001;410:944 – 948.
113. Chiang SH, Hou JC, Hwang J, et al.: Cloning and functional characterization of related TC10 isoforms, a subfamily of Rho proteins involved in insulin-stimulated glucose transport. *The Journal of Biological Chemistry* 2002;277:13067 – 13073.
114. Chang L, Adams RD, Saltiel AR: The TC10-interacting protein CIP4/2 is required for insulin-stimulated Glut4 translocation in 3T3L1 adipocytes. *PNAS* 2002;99:12835–12840.
115. Kanzaki M, Watson RT, Hou JC, et al.: Small GTP-binding protein TC10 differentially regulates two distinct populations of filamentous actin in 3T3L1 adipocytes. *Molecular Biology of the Cell* 2002;13:2334 – 2346.

116. Kimura A, Baumann CA, Chiang SH, Saltiel AR: The sorbin homology domain: a motif for the targeting of proteins to lipid rafts. *PNAS* 2001;98:9098–9103.
117. Gustavsson J, Parpal S, Stralfors P: Insulin-stimulated glucose uptake involves the transition of glucose transporters to a caveolae-rich fraction within the plasma membrane: implications for type II diabetes. *Molecular Medicine* 1996;2:367–372.
118. Watson RT, Shigematsu S, Chiang SH, et al.: Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. *Journal of Cell Biology* 2001;154:829 – 840.
119. Hayashi T, Wojtaszewski JF, Goodyear LJ: Exercise regulation of glucose transport in skeletal muscle. *American Journal of Physiology* 1997;273:E1039–1051.
120. Goodyear LJ: Amp-activated protein kinase: a critical signaling intermediary for exercise-stimulated glucose transport? *Exercise and Sport Sciences Reviews* 2000;28:113–116.
121. Merrill GF, Kurth EJ, Hardie DG, Winder WW: AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. *American Journal of Physiology* 1997;273:E1107 – 1112.
122. Mu J, Brozinick JT,Jr, Valladares O,etal.: A Role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. *Molecular Cell* 2001;7:1085–1094.
123. Hardie DG, Carling D, Carlson M: The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? *Annual Review of Biochemistry* 1998;67:821–855.
124. Kramer HF, Witczak CA, Fujii N, et al.: Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. *Diabetes* 2006;55:2067–2076.
125. Cartee GD, Wojtaszewski JF: Role of Akt substrate of 160 Kda in insulin-stimulated and contraction-stimulated glucose transport. *Applied Physiology, Nutrition, and Metabolism* 2007;32:557–566.
126. Middelbeek RJ, Chambers MA, Tantiwong P,etal.: Insulin stimulation regulates AS160 and TBC1D1 phosphorylation sites in human skeletal muscle. *Nutrition & Diabetes* 2013;3:e74.
127. Kramer HF, Witczak CA, Taylor EB, et al.:AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. *The Journal of Biological Chemistry* 2006;281:31478 – 31485.
128. Ducommun S, Wang HY, Sakamoto K, et al.: Thr649Ala-AS160 knock-in mutation does not impair contraction/AICAR-induced glucose transport in mouse muscle. *American Journal of Physiology - Endocrinology and Metabolism* 2012;302:E 1036 – 1043.
129. Taylor EB, An D, Kramer HF, et al.: Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse

skeletal muscle. *The Journal of Biological Chemistry* 2008;283:9787 – 9796.
130. Treebak JT, Taylor EB, Witczak CA, et al.: Identification of a novel phosphorylation site on TBC1D4 regulated by AMP-activated protein kinase in skeletal muscle. *American Journal of Physiology - Cell Physiology* 2010;298:C377–385.
131. Tan SX, Ng Y, Burchfield JG, et al.: The Rab Gtpase-activating protein TBC1D4/AS160 contains an atypical phosphotyrosine- binding domain that interacts with plasma membrane phospholipids to facilitate Glut4 trafficking in adipocytes. *Molecular and Cellular Biology* 2012;32:4946–4959.
132. Pfeffer S, Aivazian D: Targeting Rab Gtpases to distinct membrane compartments. *Nature Reviews Molecular Cell Biology* 2004;5:886 – 896.
133. Stenmark H: Rab Gtpases as coordinators of vesicle traffic. *Nature Reviews Molecular Cell Biology* 2009;10:513–525.
134. Zerial M, McBride H: Rab proteins as membrane organizers. *Nature Reviews Molecular Cell Biology* 2001;2:107–117.
135. Garvey WT, Birnbaum MJ: Cellular insulin action and insulin resistance. *Baillières Clinical Endocrinology and Metabolism* 1993;7:785 – 873.
136. Ing BL,Chen H, Robinson KA,et al.:Characterization of a mutant Glut4 lacking the N-glycosylation site: studies in transfected rat adipose cells. *Biochemical and Biophysical Research Communications* 1996;218:76–82.
137. Haga Y, Ishii K, Suzuki T: N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter Glut4. *The Journal of Biological Chemistry* 2011;286:31320–31327.
138. Williams D, Hicks SW, Machamer CE, Pessin JE: Golgin-160 is required for the Golgi membrane sorting of the insulin-responsive glucose transporter GLUT4 in adipocytes. *Molecular Biology of the Cell* 2006;17:5346–5355.
139. Rea S, James DE: Moving Glut4: the biogenesis and trafficking of Glut4 storage vesicles. *Diabetes* 1997;46:1667–1677.
140. Mora S, Pessin JE: An adipocentric view of signaling and intracellular trafficking. *Diabetes/Metabolism Research and Reviews* 2002;18:345 – 356.
141. Bao S, Smith RM, Jarett L, Garvey WT: The effects of Brefeldin A on the glucose transport system in rat adipocytes. Implications regarding the intracellular locus of insulin-sensitive Glut4. *The Journal of Biological Chemistry* 1995;270:30199–30204.
142. Martin LB, Shewan A, Millar CA, et al.: Vesicle-associated membrane protein 2 plays a specific role in the insulin-dependent trafficking of the facilitative glucose transporter Glut4 in 3T3-L1 adipocytes. *The Journal of Biological Chemistry* 1998;273: 1444 – 1452.
143. Kandror KV, Pilch PF: Compartmentalization of protein traffic in insulin-sensitive cells. *American Journal of Physiology* 1996; 271:E1 – 14.

144. Rice JE, Livingstone C, Gould GW: Trafficking, targeting and translocation of the insulin-responsive glucose transporter, Glut4, in adipocytes. *Biochemical Society Transactions* 1996;24:540 – 546.
145. Holman GD, Kasuga M: From receptor to transporter: insulin signalling to glucose transport. *Diabetologia* 1997;40:991 – 1003.
146. Malide D, Dwyer NK, Blanchette-Mackie EJ, Cushman SW: Immunocytochemical evidence that Glut4 resides in a specialized translocation post-endosomal vamp2-positive compartment in rat adipose cells in the absence of insulin. *Journal of Histochemistry & Cytochemistry* 1997;45:1083 – 1096.
147. Aledo JC, Lavoie L, Volchuk A, et al.: Identification and characterization of two distinct intracellular GLUT4 pools in rat skeletal muscle: evidence for an endosomal and an insulin-sensitive GLUT4 compartment. *Biochemistry Journal* 1997;325(Pt 3):727 – 732.
148. Watson RT, Pessin JE: Subcellular compartmentalization and trafficking of the insulin-responsive glucose transporter, GLUT4. *Experimental Cell Research* 2001;271:75–83.
149. Zaarour N, Berenguer M, LeMarchand-Brustel Y, Govers R: Deciphering the role of GLUT4 N-glycosylation in adipocyte and muscle cell models. *Biochemistry Journal* 2012;445:265–273.
150. Shewan AM, Marsh BJ, Melvin DR,et al.: The cytosolic C-terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal. *Biochemistry Journal* 2000;350(Pt 1):99–107.
151. Lee W, Jung CY: A synthetic peptide corresponding to the GLUT4 C-terminal cytoplasmic domain causes insulin-like glucose transport stimulation and GLUT4 recruitment in rat adipocytes. *The Journal of Biological Chemistry* 1997;272: 21427 – 21431.
152. Sadler JB, Bryant NJ, Gould GW, Welburn CR: Posttranslational modifications of GLUT4 affect its subcellular localization and translocation. *International Journal of Molecular Sciences* 2013;14:9963 – 9978.
153. Lamb CA, McCann RK, Stockli J, et al.: Insulin-regulated trafficking of GLUT4 requires ubiquitination. *Traffic* 2010;11:1445–1454.
154. Liu LB, Omata W, Kojima I, Shibata H: The SUMO conjugating enzyme Ubc9 is a regulator of GLUT4 turnover and targeting to the insulin-responsive storage compartment in 3T3-L1 adipocytes. *Diabetes* 2007;56:1977–1985.
155. Giorgino F, deRobertis O, Laviola L,etal.:The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. *PNAS* 2000;97:1125–1130.
156. Ren W, Jhala US, Du K: Proteomic analysis of protein palmitoylation in adipocytes. *Adipocyte* 2013;2:17–28.
157. Kandror KV, Pilch PF: Gp160, a tissue-specific marker for insulin-activated glucose transport. *PNAS* 1994;91:8017–8021.

158. Martin S, Rice JE, Gould GW, et al.: The glucose transporter GLUT4 and the aminopeptidase vp165 colocalise in tubulo-vesicular elements in adipocytes and cardiomyocytes. *Journal of Cell Science* 1997;110(Pt 18):2281–2291.
159. Lin BZ, Pilch PF, Kandror KV: Sortilin is a major protein component of GLUT4-containing vesicles. *The Journal of Biological Chemistry* 1997;272:24145-7.
160. Jedrychowski MP, Gartner CA, Gygi SP, et al.: Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling. *The Journal of Biological Chemistry* 2010;285:104–114.
161. Sollner TH, Rothman JE: Molecular machinery mediating vesicle budding, docking and fusion. *Cell Structure and Function* 1996;21:407 – 412.
162. Pevsner J, Hsu SC, Braun JE, et al.: Specificity and regulation of a synaptic vesicle docking complex. *Neuron* 1994;13:353 – 361.
163. Novick P, Zerial M: The diversity of Rab proteins in vesicle transport. *Current Opinion in Cell Biology* 1997;9:496 – 504.
164. Seabra MC, Mules EH, Hume AN: Rab Gtpases, intracellular traffic and disease. *Trends in Molecular Medicine* 2002;8:23 – 30.
165. Cormont M, Bortoluzzi MN, Gautier N, et al.: Potential role of Rab4 in the regulation of subcellular localization of GLUT4 in adipocytes. *Molecular and Cellular Biology* 1996;16:6879 – 6886.
166. Shibata H, Omata W, Suzuki Y, et al.: A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain inhibits insulin action on glucose transport in rat adipocytes. *The Journal of Biological Chemistry* 1996;271:9704–9709.
167. Wang Q, Bilan PJ, Tsakiridis T, et al.: Actin filaments participate in the relocalization of phosphatidylinositol 3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. *Biochemistry Journal* 1998;331(Pt 3):917–928.
168. Kanzaki M, Pessin JE: Insulin-stimulated GLUT4 translocation in adipocytes is dependent upon cortical actin remodeling. *The Journal of Biological Chemistry* 2001;276:42436–42444.
169. Jiang ZY, Chawla A, Bose A, et al.: A phosphatidylinositol 3-kinase-independent insulin signaling pathway to N-WASP/ Arp2/3/F-Actin required for GLUT4 glucose transporter recycling. *The Journal of Biological Chemistry* 2002;277:509–515.
170. Brozinick JT, Jr, Hawkins ED, Strawbridge AB, Elmendorf JS: Disruption of cortical actin in skeletal muscle demonstrates an essential role of the cytoskeleton in glucose transporter 4 translocation in insulin-sensitive tissues. *The Journal of Biological Chemistry* 2004;279:40699–40706.
171. Murphy GA,Solski PA, Jillian SA, et al.:Cellular functions of TC10, a Rho family Gtpase: regulation of morphology, signal transduction and cell growth. *Oncogene* 1999;18:3831–3845.

172. Semiz S, Park JG, Nicoloro SM,et al.:Conventional kinesin KIF5B mediates insulin-stimulated GLUT4 movements on microtubules. *EMBO Journal* 2003;22:2387–2399.
173. Olson AL, Trumbly AR, Gibson GV: Insulin-mediated GLUT4 translocation is dependent on the microtubule network. *The Journal of Biological Chemistry* 2001;276:10706–10714.
174. Xu YK, Xu KD, Li JY, et al.: Bidirectional transport of GLUT4 vesicles near the plasma membrane of primary rat adipocytes. *Biochemical and Biophysical Research Communications* 2007; 359:121 – 128.
175. Shigematsu S, Khan AH, Kanzaki M, Pessin JE: Intracellular insulin-responsive glucose transporter (GLUT4) distribution but not insulin-stimulated GLUT4 exocytosis and recycling are microtubule dependent. *Molecular Endocrinology* 2002;16:1060–1068.
176. Huang J, Imamura T, Olefsky JM: Insulin can regulate GLUT4 internalization by signaling to Rab5 and the motor protein dynein. *PNAS* 2001;98:13084–13089.
177. Emoto M, Langille SE, Czech MP: A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes. *The Journal of Biological Chemistry* 2001; 276:10677 – 10682.
178. Imamura T, Huang J, Usui I, et al.: Insulin-induced GLUT4 translocation involves protein kinase C-lambda-mediated functional coupling between Rab4 and the motor protein kinesin. *Molecular and Cellular Biology* 2003;23:4892 – 4900.
179. Bogan JS, Hendon N, McKee AE, et al.: Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking. *Nature* 2003;425:727 – 733.
180. Inoue M, Chang L, Hwang J, et al.: The exocyst complex is required for targeting of GLUT4 to the plasma membrane by insulin. *Nature* 2003;422:629 – 633.
181. He B, Guo W: The exocyst complex in polarized exocytosis. *Current Opinion in Cell Biology* 2009;21:537 – 542.
182. Lizunov VA, Matsumoto H, Zimmerberg J, et al.: Insulin stimulates the halting, tethering, and fusion of mobile GLUT4 vesicles in rat adipose cells. *Journal of Cell Biology* 2005;169:481 – 489.
183. Lopez JA, Burchfield JG, Blair DH, et al.: Identification of a distal GLUT4 trafficking event controlled by actin polymerization. *Molecular Biology of the Cell* 2009;20:3918 – 3929.
184. Dawicki-McKenna JM, Goldman YE, Ostap EM: Sites of glucose transporter-4 vesicle fusion with the plasma membrane correlate spatially with microtubules. *PLoS ONE* 2012;7:e43662.
185. Langlais P, Dillon JL, Mengos A, et al.: Identification of a role for CLASP2 in insulin action. *The Journal of Biological Chemistry* 2012;287:39245 – 39253.

186. Talior-Volodarsky I, Randhawa VK, Zaid H, Klip A: Alpha- actinin-4 is selectively required for insulin-induced GLUT4 translocation. *The Journal of Biological Chemistry* 2008;283: 25115 – 25123.
187. DeFronzo RA, Tripathy D: Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* 2009;32(Suppl 2):S157 – 163.
188. Garvey WT, Hermayer KL (1998) Clinical implications of the insulin resistance syndrome. *Clinical Cornerstone* 1998;1:13 – 28.
189. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *Journal of Clinical Investigation* 2000;105:311 – 320.
190. Zierath JR, Krook A, Wallberg-Henriksson H: Insulin action and insulin resistance in human skeletal muscle. *Diabetologia* 2000;43:821 – 835.
191. Jiang ZY, Lin YW, Clemont A, et al.: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. *Journal of Clinical Investigation* 1999;104:447 – 445.
192. De Fea K, Roth RA: Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. *The Journal of Biological Chemistry* 1997;272: 31400 – 31406.
193. Nolan JJ, Ludvik B, Beerdsen P, et al.: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. *New England Journal of Medicine* 1994;331:1188 – 1189.
194. Turcotte LP, Fisher JS: Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. *Journal of Physical Therapy* 2008;88:1279 – 1296.
195. Yassine HN, Marchetti CM, Krishnan RK, et al.: Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults: a randomized clinical trial. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences* 2009;64:90 – 95.
196. Pratipanawatr T, Cusi K, Ngo P, et al.: Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. *Diabetes* 2002;51:462 – 468.
197. Andersen DK, Hundal RS, Rothman DL, et al.: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *Journal of Clinical Investigation* 1999;103:253 – 259.
198. Yi Z, Langlais P, De Filippis EA, et al.: Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle. *Diabetes* 2007;56:1508 – 1516.
199. Langlais P, Yi Z, Finlayson J, et al.: Global IRS-1 phosphorylation analysis in insulin resistance. *Diabetologia* 2011;54:2878 – 2889.
200. Humphrey SJ, Yang G, Yang P, et al.: Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. *Cell Metabolism* 2013;17:1009 – 1020.

201. Hunter SJ, Garvey WT: Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. *American Journal of Medicine* 1998;105:331 – 345.
202. Garvey WT, Maianu L, Huecksteadt TP, et al.: Pre-translational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. *Journal of Clinical Investigation* 1991;87:1072 – 1081.
203. Garvey WT, Maianu L, Hancock JA, et al.: Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. *Diabetes* 1992;41:465 – 475.
204. Garvey WT, Maianu L, Zhu JH, et al.: Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters. *Diabetes* 1993;42:1773 – 1785.
205. Garvey WT, Maianu L, Zhu JH, et al.: Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. *Journal of Clinical Investigation* 1998;101:2377 – 2386.
206. Maianu L, Keller SR, Garvey WT: Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. *Journal of Clinical Endocrinology & Metabolism* 2001;86:5450 – 5456.
207. Tanti JF, Gremeaux T, van Obberghen E, Le Marchand-Brustel Y: Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. *The Journal of Biological Chemistry* 1994;269:6051 – 6057.
208. Mothe I, Van Obberghe E: Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. *The Journal of Biological Chemistry* 1996;271:11222 – 11227.
209. Paz K, Hemi R, LeRoith D, et al.: A molecular basis for insulin resistance. elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. *The Journal of Biological Chemistry* 1997;272:29911 – 29918.
210. Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. *Current Opinion in Pharmacology* 2009;9:753 – 762.
211. Liu YF, Paz K, Herschkovitz A, et al.: Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-

attenuated mechanism to negatively regulate the function of IRS proteins. *The Journal of Biological Chemistry* 2001;276:14459 – 14465.
212. Ravichandran LV, Esposito DL, Chen J, Quon MJ: Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. *The Journal of Biological Chemistry* 2001;276:3543 – 3549.
213. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 1993;259:87 – 91.
214. Saghizadeh M, Ong JM, Garvey WT,et al.:The expression of TNF alpha by human muscle. Relationship to insulin resistance. *Journal of Clinical Investigation* 1996;97:1111–1116.
215. Hotamisligil GS, Peraldi P, Budavari A ,et al.:IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. *Science* 1996;271:665 – 668.
216. Kanety H, Feinstein R, Papa MZ, et al.: Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. *The Journal of Biological Chemistry* 1995;270:23780–23784.
217. Peraldi P, Xu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. *Journal of Clinical Investigation* 1997;100:1863–1869.
218. Aguirre V, Werner ED, Giraud J,et al.:Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. *The Journal of Biological Chemistry* 2002;277:1531–1537.
219. Peraldi P, Hotamisligil GS, Buurman WA, et al.: Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the P55 TNF receptor and activation of sphingomyelinase. *The Journal of Biological Chemistry* 1996;271:13018–13022.
220. Hundal RS , Petersen KF, Mayerson AB, et al.:Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. *Journal of Clinical Investigation* 2002;109:1321–1326.
221. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. *Science* 2001;293:1673–1677.
222. Kim JK, Kim YJ, Fillmore JJ, et al.: Prevention of fat-induced insulin resistance by salicylate. *Journal of Clinical Investigation* 2001;108:437 – 446.
223. Asante-Appiah E, Kennedy BP: Protein tyrosine phosphatases: the quest for negative regulators of insulin action. *American Journal of Physiology - Endocrinology and Metabolism* 2003;284:E663–670.
224. Ahmad F, Azevedo JL, Cortright R, et al.: Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-

resistant human obesity and diabetes. *Journal of Clinical Investigation* 1997;100:449–458.
225. Goldstein BJ, Ahmad F, Ding W, et al.: Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. *Molecular and Cellular Biochemistry* 1998;182:91–99.
226. Drake PG, Posner BI: Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. *Molecular and Cellular Biochemistry* 1998;182:79 – 89.
227. Elchebly M, Payette P, Michaliszyn E, et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. *Science* 1999;283:1544 – 1548.
228. Emanuelli B, Peraldi P, Filloux C, et al.: SOCS-3 is an insulin-induced negative regulator of insulin signaling. *The Journal of Biological Chemistry* 2000;275:15985 – 15991.
229. Starr R, Willson TA, Viney EM, et al.: A family of cytokine-inducible inhibitors of signalling. *Nature* 1997;387:917 – 921.
230. Luger A, Prager R, Gaube S, et al.: Decreased peripheral insulin sensitivity in acromegalic patients. *Experimental and Clinical Endocrinology* 1990;95:339 – 343.
231. Cohen B, Novick D, Rubinstein M: Modulation of insulin activities by leptin. *Science* 1996;274:1185 – 1188.
232. GoldfineI D, Maddux BA, Youngren JF, et al.:Membrane glycoprotein PC-1 and insulin resistance. *Molecular and Cellular Biochemistry* 1998;182:177–184.
233. Frittitta L, Spampinato D, Solini A, et al.: Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. *Diabetes* 1998;47:1095–1100.
234. Kumakura S, Maddux BA, Sung CK: Overexpression of membrane glycoprotein PC-1 can influence insulin action at a post-receptor site. *The Journal of Biological Chemistry* 1998;68:366–377.
235. Youngren JF, Maddux BA, Sasson S, et al.: Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport. *Diabetes* 1996;45:1324–1328.
236. O'Brien RM, Streeper RS, Ayala JE, et al.: Insulin-regulated gene expression. *Biochemical Society Transactions* 2001;29:552–558.
237. Lochhead PA, Coghlan M, Rice SQ, Sutherland C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolpyruvate carboxykinase gene expression. *Diabetes* 2001;50:937–946.
238. Pearson G, Robinson F, Beers Gibson T, et al.: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocrine Reviews* 2001;22:153–183.

239. Paradis S, Ruvkun G: *Caenorhabditis elegans* Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. *Genes & Development* 1998;12:2488–2498.
240. Anderson MJ, Viars CS, Czekay S, et al.:Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. *Genomics* 1998;47:187–199.
241. Tang ED, Nunez G, Barr FG, Guan KL: Negative regulation of the forkhead transcription factor FKHR by Akt. *The Journal of Biological Chemistry* 1999;274:16741–16746.
242. Guo S, Rena G, Cichy S, et al.: Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. *The Journal of Biological Chemistry* 1999;274:17184–17192.
243. Hall RK, Yamasaki T, Kucera T, et al.: Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. *The Journal of Biological Chemistry* 2000; 275:30169 – 30175.
244. Yeagley D, Guo S, Unterman T, Quinn PG: Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. *The Journal of Biological Chemistry* 2001;276:33705 – 33710.
245. Puigserver P, Wu Z, Park CW, et al.: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 1998;92:829 – 839.
246. Yoon JC, Puigserver P, Chen G, et al.: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 2001;413:131 – 138.
247. Herzig S, Long F, Jhala US, et al.: Creb regulates hepatic gluconeogenesis through the coactivator PGC-1. *Nature* 2001;413: 179 – 183.
248. Puigserver P, Rhee J, Donovan J, et al.: Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. *Nature* 2003;423:550 – 555.
249. Kitamura T, Nakae J, Kitamura Y, et al.: The forkhead transcription factor FOXO1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. *Journal of Clinical Investigation* 2002;110:1839 – 1847.
250. Nakae J, Kitamura T, Kitamura Y, et al.: The forkhead transcription factor FOXO1 regulates adipocyte differentiation. *Developmental Cell* 2003;4:119 – 129.
251. Wang X, Sato R, Brown MS, et al.: SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. *Cell* 1994;77:53 – 62.

252. Hua X, Wu J, Goldstein JL, et al.: Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBP1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. *Genomics* 1995;25:667 – 673.
253. Tontonoz P, Kim JB, Graves RA, Spiegelman BM: ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. *Molecular and Cellular Biology* 1993;13:4753 – 4759.
254. Brown MS, Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *PNAS* 1999; 96:11041 – 11048.
255. Horton JD, Bashmakov Y, Shimomura I, Shimano H: Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. *PNAS* 1998;95:5987 – 5992.
256. Kim JB, Sarraf P, Wright M, et al.: Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. *Journal of Clinical Investigation* 1998;101:1 – 9.
257. Foretz M, Pacot C, Dugail I, et al.: ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. *Molecular and Cellular Biology* 1999;19:3760 – 3768.
258. Matsumoto M, Ogawa W, Teshigawara K, et al.: Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. *Diabetes* 2002;51:1672 – 1680.
259. Foufelle F, Ferre P: New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. *Biochemical Journal* 2002;366:377 – 391.
260. Sawka-Verhelle D, Filloux C, Tartare-Deckert S, et al.: Identification of Stat 5B as a substrate of the insulin receptor. *European Journal of Biochemistry* 1997;250:411 – 417.
261. Sawka-Verhelle D, Tartare-Deckert S, Decaux JF, et al.: Stat 5B, activated by insulin in a Jak-independent fashion, plays a role in glucokinase gene transcription. *Endocrinology* 2000; 141:1977 – 1988.